[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3ZOw4smyvXIq532HqCrqAVc7Y6iH0vcbIM4-K97BxgA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.",[4],75,false,24,2,15140,65,[13,16,19,22,24,27,30,32],{"name":14,"count":15},"Autism Spectrum Disorder",12,{"name":17,"count":18},"ADHD",6,{"name":20,"count":21},"Anxiety",5,{"name":23,"count":21},"Spinal Cord Injury",{"name":25,"count":26},"Spinal Cord Injuries",4,{"name":28,"count":29},"Cerebellar Ataxia",3,{"name":31,"count":29},"Stroke",{"name":33,"count":29},"Hemiparesis",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07221968","Melatonin for the Treatment of DEE-SWAS","2028-07-01","Melatonin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07594652","Medication Treatment of ADHD in Pediatric Epilepsy","2030-12","methylphenidate hydrochloride",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,77,101,127,151,188,216,234,259,284],{"intervention":44,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":65,"NA":75},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":58},[],{"trials":66,"activeCount":54,"soonestReadout":43},[67],{"nctId":41,"briefTitle":42,"status":68,"phases":69,"primaryCompletion":43,"completion":43,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[50],"2026-05",25,[73],"ADHD - Attention Deficit Disorder With Hyperactivity",[44],{"trials":76,"activeCount":58},[],{"intervention":39,"totalTrials":54,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":80,"activeCount":58},[],{"trials":82,"activeCount":58},[],{"trials":84,"activeCount":54,"soonestReadout":38},[85],{"nctId":36,"briefTitle":37,"status":86,"phases":87,"primaryCompletion":38,"completion":88,"start":89,"enrollment":29,"conditions":90,"interventions":94},"NOT_YET_RECRUITING",[48],"2028-12-30","2026-07-01",[91,92,93],"CSWS","Developmental and\u002For Epileptic Encephalopathies","Electrical Status Epilepticus in Sleep",[39],{"trials":96,"activeCount":58},[],{"trials":98,"activeCount":58},[],{"trials":100,"activeCount":58},[],{"intervention":102,"totalTrials":54,"cells":103},"Clobazam",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":125},{"trials":105,"activeCount":58},[],{"trials":107,"activeCount":58},[],{"trials":109,"activeCount":58},[],{"trials":111,"activeCount":58},[],{"trials":113,"activeCount":58},[114],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT03371836","Use of Clobazam for Epilepsy and Anxiety","COMPLETED",[50],"2019-12-31","2017-10-01",20,[123,20],"Epilepsy",[102],{"trials":126,"activeCount":58},[],{"intervention":128,"totalTrials":54,"cells":129},"Cannabidiol 100 MG\u002FML",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":149},{"trials":131,"activeCount":58},[],{"trials":133,"activeCount":58},[],{"trials":135,"activeCount":58},[],{"trials":137,"activeCount":58},[],{"trials":139,"activeCount":58},[140],{"nctId":141,"briefTitle":142,"status":117,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":121,"conditions":147,"interventions":148},"NCT05324449","Epidiolex® for Anxiety in Pediatric Epilepsy",[50],"2025-03-17","2025-05-05","2022-04-05",[20,123],[128],{"trials":150,"activeCount":58},[],{"intervention":152,"totalTrials":9,"cells":153},"dextromethorphan",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":182,"PHASE4":184,"NA":186},{"trials":155,"activeCount":58},[],{"trials":157,"activeCount":58},[],{"trials":159,"activeCount":58},[160,170],{"nctId":161,"briefTitle":162,"status":117,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT01520363","Placebo Controlled Trial of Dextromethorphan in Rett Syndrome",[48],"2016-10-26","2012-03",57,[168],"Rett Syndrome",[152],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT00593957","Trial of Dextromethorphan in Rett Syndrome","TERMINATED",[48],"2010-04","2010-06","2004-08",38,[168],[181,181],"Dextromethorphan",{"trials":183,"activeCount":58},[],{"trials":185,"activeCount":58},[],{"trials":187,"activeCount":58},[],{"intervention":189,"totalTrials":54,"cells":190},"Sirolimus",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":192,"activeCount":58},[],{"trials":194,"activeCount":58},[],{"trials":196,"activeCount":58},[197],{"nctId":198,"briefTitle":199,"status":117,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":29,"conditions":204,"interventions":208},"NCT01929642","Rapalogues for Autism Phenotype in TSC: A Feasibility Study",[48],"2016-07","2016-08","2013-07",[205,206,207],"Tuberous Sclerosis Complex","Self-injury","Autism",[189,209],"Everolimus",{"trials":211,"activeCount":58},[],{"trials":213,"activeCount":58},[],{"trials":215,"activeCount":58},[],{"intervention":209,"totalTrials":54,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":219,"activeCount":58},[],{"trials":221,"activeCount":58},[],{"trials":223,"activeCount":58},[224],{"nctId":198,"briefTitle":199,"status":117,"phases":225,"primaryCompletion":201,"completion":202,"start":203,"enrollment":29,"conditions":226,"interventions":227},[48],[205,206,207],[189,209],{"trials":229,"activeCount":58},[],{"trials":231,"activeCount":58},[],{"trials":233,"activeCount":58},[],{"intervention":235,"totalTrials":54,"cells":236},"Sildenafil",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":238,"activeCount":58},[],{"trials":240,"activeCount":58},[],{"trials":242,"activeCount":58},[243],{"nctId":244,"briefTitle":245,"status":173,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":121,"conditions":249,"interventions":252},"NCT01168908","Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy",[48],"2014-01","2010-09",[250,251],"Duchenne Muscular Dystrophy","Becker Muscular Dystrophy",[235],{"trials":254,"activeCount":58},[],{"trials":256,"activeCount":58},[],{"trials":258,"activeCount":58},[],{"intervention":260,"totalTrials":54,"cells":261},"glyceryl trierucate\u002Fglyceryl trioleate",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":278,"PHASE4":280,"NA":282},{"trials":263,"activeCount":58},[],{"trials":265,"activeCount":58},[],{"trials":267,"activeCount":58},[268],{"nctId":269,"briefTitle":270,"status":173,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT00004418","Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy",[48],"2014-12","1998-04",126,[276],"Adrenoleukodystrophy",[260],{"trials":279,"activeCount":58},[],{"trials":281,"activeCount":58},[],{"trials":283,"activeCount":58},[],{"intervention":285,"totalTrials":54,"cells":286},"Omega-3 Fatty Acids",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":288,"activeCount":58},[],{"trials":290,"activeCount":58},[],{"trials":292,"activeCount":58},[293],{"nctId":294,"briefTitle":295,"status":117,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":166,"conditions":300,"interventions":303},"NCT01694667","Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder",[48],"2012-12","2013-05","2012-09",[301,302],"Autism Spectrum Disorders","Hyperactivity",[285],{"trials":305,"activeCount":58},[],{"trials":307,"activeCount":58},[],{"trials":309,"activeCount":58},[]]